Prosecution Insights
Last updated: July 17, 2026
Application No. 18/279,796

PYRIDINE DERIVATIVES USEFUL AS HCN2 MODULATORS

Final Rejection §112
Filed
Aug 31, 2023
Priority
Mar 03, 2021 — GB 2103017.6 +2 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
King's College London
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1427 granted / 1766 resolved
+20.8% vs TC avg
Minimal -15% lift
Without
With
+-15.3%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
52 currently pending
Career history
1809
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
27.9%
-12.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1766 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . According to paper filed on May 1, 2026, the applicants have canceled claims 22, 24, 25 and 30; amended claims 1, 3, 4, 6-8, 10-21, 23 and 26-29 and furthermore, have added a new claim 31. Claims 1-21, 23, 26-29 and 31 are pending in the application. Response to Arguments Applicant's arguments filed May 1, 2026 have been fully considered but they are not persuasive regarding indefiniteness rejection of claim 26. The applicants have amended claims to overcome all other rejections. Regarding claim 26, the applicants argue on page 14 that POSITA would know from the disclosure and in view of common knowledge in the art regarding specific diseases mediated by HCN2. The examiner does not agree with these arguments since there may be enablement issues based on specific diseases mediated either by hyperactivity or hypoactivity of HCN2. Therefore, claim must include specific diseases mediated by either hyperactivity or hypoactivity of HCN2. Conclusion Rejection of claim 26 under 35 U.S.C. 112, 2nd paragraph is maintained. Allowable Subject Matter Claim 27 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 1-21, 23, 28-29 and 31 are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Aug 31, 2023
Application Filed
Dec 03, 2025
Non-Final Rejection mailed — §112
May 01, 2026
Response Filed
May 21, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679846
NOVEL XANTHONE COMPOUND HAVING EXCELLENT ANTICANCER EFFECT
2y 7m to grant Granted Jul 14, 2026
Patent 12673924
VALIOLAMINE DERIVATIVES AS GLUCOSIDASE INHIBITORS
2y 10m to grant Granted Jul 07, 2026
Patent 12667564
PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA, BETA-UNSATURATED KETONE COMPOUNDS
4y 7m to grant Granted Jun 30, 2026
Patent 12668595
AZA-ERGOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
2y 11m to grant Granted Jun 30, 2026
Patent 12662479
COMPOUNDS AND USES THEREOF
3y 11m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-15.3%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1766 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month